These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 9751337

  • 21. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD, Sosa RE, Vaughan ED, Scherr DS.
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [Abstract] [Full Text] [Related]

  • 22. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?
    Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W.
    BJU Int; 2012 Apr; 109(7):1026-30. PubMed ID: 21883838
    [Abstract] [Full Text] [Related]

  • 23. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP.
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [Abstract] [Full Text] [Related]

  • 24. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS.
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [Abstract] [Full Text] [Related]

  • 25. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI.
    J Clin Oncol; 2005 Sep 20; 23(27):6533-9. PubMed ID: 16116151
    [Abstract] [Full Text] [Related]

  • 26. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH, Cheng AJ, Chang Pe, Pan TL, Yung BY.
    Urology; 2004 Oct 20; 64(4):839-44. PubMed ID: 15491744
    [Abstract] [Full Text] [Related]

  • 27. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival.
    Dotan ZA, Kavanagh K, Yossepowitch O, Kaag M, Olgac S, Donat M, Herr HW.
    J Urol; 2007 Dec 20; 178(6):2308-12; discussion 2313. PubMed ID: 17936804
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.
    BJU Int; 2009 Jul 20; 104(2):179-83. PubMed ID: 19154448
    [Abstract] [Full Text] [Related]

  • 30. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.
    BJU Int; 2004 Dec 20; 94(9):1258-62. PubMed ID: 15610101
    [Abstract] [Full Text] [Related]

  • 31. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
    Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH.
    J Urol; 2009 Dec 20; 182(6):2625-30. PubMed ID: 19836779
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Outcome of very large superficial bladder tumours: a 10-year experience.
    Gupta SK, Parr NJ.
    Scand J Urol Nephrol; 2008 Dec 20; 42(3):243-8. PubMed ID: 18432531
    [Abstract] [Full Text] [Related]

  • 34. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 20; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 35. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan 20; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF.
    Urology; 2007 Sep 20; 70(3):482-6. PubMed ID: 17905101
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Treatment delay and prognosis in invasive bladder cancer.
    Liedberg F, Anderson H, Månsson W.
    J Urol; 2005 Nov 20; 174(5):1777-81; discussion 1781. PubMed ID: 16217282
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.